DePinho Ronald A Form 4 May 02, 2011

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may continue. See Instruction See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

(Last)

1. Name and Address of Reporting Person \*

2. Issu Symbol

(Middle)

5. Relationship of Reporting Person(s) to

Issuer

DePinho Ronald A

AVEO PHARMACEUTICALS INC

2. Issuer Name and Ticker or Trading

(Check all applicable)

[AVEO]

2 Data

3. Date of Earliest Transaction (Month/Day/Year)

\_\_X\_\_ Director \_\_\_\_\_ Officer (give title

2 \_\_\_\_\_ 10% Owner Other (specify

C/O AVEO PHARMACEUTICALS, 04/28/2011

(Street)

(First)

INC., 75 SIDNEY STREET

4. If Amendment, Date Original

Applicable Line)

Filed(Month/Day/Year)

\_X\_ Form filed by One Reporting Person \_\_\_ Form filed by More than One Reporting

6. Individual or Joint/Group Filing(Check

Person

CAMBRIDGE, MA 02139

(City)	(State) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned							y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price \$	Transaction(s) (Instr. 3 and 4)	(Instr. 4)	
Common Stock	04/28/2011		S(1)	10,000	D	14.6958 (2)	240,012	D	
Common Stock	04/28/2011		S <u>(1)</u>	10,000	D	\$ 15.5258 (3)	230,012	D	
Common Stock	04/28/2011		S(4)	10,000	D	\$ 14.6938 (2)	232,512	I	by spouse (5)
Common	04/28/2011		S(4)	10,000	D	\$	222,512	I	by spouse

Stock 15.5279 (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transacti	5. orNumber	6. Date Exer Expiration D		7. Titl		8. Price of Derivative	9. Nu Deriv
Security	or Exercise	(Iviolidia Day/ I car)	•	Code	of	(Month/Day		Under		Security	Secui
•			any			`	(Tear)		, ,		
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivativ			Secur		(Instr. 5)	Bene
	Derivative				Securities	\$		(Instr.	. 3 and 4)		Own
	Security				Acquired						Follo
					(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						(211512
					4, and 5)						
									Amount		
									or		
						Date	Expiration	Title	Number		
						Exercisable	Date				
									of		
				Code V	(A) $(D)$				Shares		

# **Reporting Owners**

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

DePinho Ronald A C/O AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE, MA 02139



## **Signatures**

/s/ Joseph D. Vittiglio, attorney-in-fact 05/02/2011

\*\*Signature of Reporting Person Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 8, 2011.
- (2) The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$14.50 to \$14.88, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of

Reporting Owners 2

#### Edgar Filing: DePinho Ronald A - Form 4

shares sold at each price within the ranges set forth in this footnote.

- The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$15.50 to \$15.59, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- (4) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person's spouse on March 8, 2011.
- (5) These shares are held by the reporting person's spouse. The reporting person disclaims all beneficial ownership over all such shares, except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.